Versartis, Inc. (extinct)

Versartis, Inc. (extinct)

Versartis, Inc. (extinct)

Overview
Date Founded

2008

Headquarters

275 SHORELINE DRIVE SUITE 450 REDWOOD CITY CA 94065

Type of Company

Public

Employees (Worldwide)

11 - 50

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA.

Contact Data
Trying to get in touch with decision makers at Versartis, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Paths to Versartis, Inc.
Potential Connections via
Relationship Science
You
Versartis, Inc.
Recent Transactions
Details Hidden

Versartis, Inc. purchases Aravive Biologics, Inc.

Details Hidden

Versartis, Inc. issued Common Stock

Details Hidden

Versartis, Inc. issued Common Stock

Transaction Advisors
Underwriter

Advised onVersartis, Inc. issued Common Stock

Escrow Agent

Advised onVersartis, Inc. issued Common Stock

Underwriter

Advised onVersartis, Inc. issued Common Stock

Legal Advisor

Advised onVersartis, Inc. issued Common Stock

Associate

Advised onVersartis, Inc. issued Common Stock

Associate

Advised onVersartis, Inc. issued Common Stock

Advisors & Consultants
Scientific Advisor

President & Chief Executive Officer at Ilypsa, Inc.

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Real Estate Agent

Managing Director at Newmark Knight Frank

Investors
Details Hidden

Index is an active manager which focuses young information technology and life sciences companies in Europe, Israel and the US, which have the potential to become global players in their market. The firm typically co-invests with local venture capitalists outside Europe.Index invests USD 3 to 20 million, with the possibility of investing smaller amounts in seed rounds, such as USD 300 to 500 thousand. They acquire minority stakes (20% on average) and are active board members. Their initial investment focus is on series A and B rounds and they also participate in follow-up investments at later stages for companies that successfully execute their business plans.Index generally invests in six to ten new investments a year, holds investments for three to five years and seeks exits through IPOs and trade sales.

Details Hidden

AVP invests in venture and growth investment in two sectors: life sciences and technology companies. AVP focuses on venture investment at both the early and late stage and has an active 'hands-on' involvement from a team of professionals who know the industries in which they are investing and who use their extensive networks to deliver success. They provide financing for growth capital and early stage capital requirements.

Details Hidden

Aisling Capital LLC invests in private and small cap publicly traded equities located in the US. The firm targets companies operating in the fields of developing & commercializing important and innovative healthcare products, services & technologies. It provides equity, debt and other structured securities financing for royalty deals, large cap leveraged buyout, seed and venture financing of development stage companies.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Versartis, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Versartis, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Versartis, Inc..